¶ title: Neuromyelitis Optica Spectrum Disorder (NMOSD)
description: Comprehensive review of neuromyelitis optica spectrum disorder including pathophysiology, clinical features, diagnosis, treatment, and relationship to MOGAD
published: true
tags: [demyelination, autoimmunity, optic-nerve, spinal-cord, aquaporin-4]
editor: markdown
pageId: 1018
dateCreated: "2026-02-27T01:09:06.130Z"
dateUpdated: "2026-03-23T18:54:00.000Z"
Neuromyelitis optica spectrum disorder (NMOSD), formerly known as Devic's disease, is a rare autoimmune demyelinating disorder of the central nervous system characterized by severe inflammation of the optic nerves (optic neuritis) and spinal cord (myelitis) 1. Once considered a variant of multiple sclerosis, NMOSD is now recognized as a distinct entity with unique pathophysiology, clinical course, and treatment approaches 2.
The key pathogenic feature of NMOSD is the presence of autoantibodies against aquaporin-4 (AQP4), the most abundant water channel in the central nervous system, located primarily on astrocytes 3. These antibodies drive a complement-mediated inflammatory process that leads to destructive lesions in the optic nerves, spinal cord, and other CNS regions.
- Prevalence: 1-10 per 100,000 population 4
- Geographic variation: Higher prevalence in Asian, African, and Latin American populations
- Age of onset: Mean 30-40 years (range: <10 to >70)
- Gender distribution: Strong female predominance (F:M = 9:1)
- Ethnicity: More common in non-European populations
¶ Aquaporin-4 and Astrocyte Biology
The AQP4 gene encodes aquaporin-4, a water channel protein highly expressed on astrocytic end-feet in the brain and spinal cord 5:
- Location: Perivascular and pial astrocyte processes
- Function: Water homeostasis, glutamate clearance, potassium buffering
- Expression: Highest in optic nerve, spinal cord, hypothalamus, circumventricular organs
¶ Autoantibody Pathogenesis
- Target: Extracellular loop of AQP4 protein
- Isotype: IgG1 (complement-fixing)
- Mechanism:
- Antibody binds AQP4 on astrocyte surface
- Activates complement cascade
- Forms membrane attack complex
- Leads to astrocyte death and demyelination
| Feature |
Description |
| Perivascular IgG deposition |
Antibody access to AQP4 |
| Necrosis |
Tissue destruction in lesions |
| Loss of AQP4 |
Antigen loss |
| Astrocyte death |
Primary target |
| Microglia activation |
Secondary inflammation |
| Complement activation |
C9neo deposition |
AQP4 Autoantibody Entry
↓
Binding to Astrocyte AQP4
↓
Complement Activation (Classical Pathway)
↓
Membrane Attack Complex Formation
↓
Astrocyte Necrosis
↓
Secondary Demyelination + Inflammatory Infiltrate
↓
Neurological Damage
Approximately 20-30% of NMOSD patients are seronegative for anti-AQP4 6:
- May have antibodies against other antigens (MOG, unknown)
- Often presents differently
- May represent a distinct entity
- Symptoms: Unilateral or bilateral vision loss
- Pain: Periorbital pain with eye movement
- Visual field defects: Often severe, can lead to blindness
- Recovery: Often incomplete, recurrences common
- Fundoscopy: Disc edema in acute phase
- Symptoms: Weakness, numbness, bowel/bladder dysfunction
- Pattern: Transverse or partial myelitis
- Spinal level: Often involves ≥3 vertebral segments (longitudinally extensive)
- Severity: Can cause complete paralysis
- Recovery: Often incomplete
| Syndrome |
Features |
Frequency |
| Area postrema syndrome |
Intractable nausea, vomiting, hiccups |
10-20% |
| Acute brainstem syndrome |
Cranial nerve deficits, respiratory dysfunction |
10-15% |
| Diencephalic syndrome |
Sleep disorders, thermoregulation |
<10% |
| Cerebral syndrome |
Encephalopathy, headache |
<10% |
- Relapsing: 80-90% of patients
- Monophasic: 10-20% (more common in children)
- Attack frequency: Variable, average 1-3 per year
- Disability accumulation: Each attack contributes to disability
- Progression: Secondary progression may occur
NMOSD attacks are typically severe:
- Optic neuritis: Often leads to significant visual impairment
- Myelitis: Commonly results in residual weakness, sensory loss
- Area postrema: Can cause life-threatening dehydration
| Clinical Criterion |
Requirement |
| Core clinical syndrome |
≥1 of: optic neuritis, acute myelitis, area postrema, acute brainstem, diencephalic, cerebral |
| Positive AQP4-IgG |
Using best available detection method |
| Exclusion |
Alternative diagnoses |
| Requirement |
Description |
| ≥2 core syndromes |
Including at least 1 of: optic neuritis, acute myelitis, area postrema |
| Dissemination in space |
MRI findings consistent |
| Positive MOG-IgG |
If present (then consider MOGAD) |
| Exclusion |
Alternative diagnoses |
| Test |
Finding |
Significance |
| AQP4-IgG (cell-based assay) |
Positive |
Diagnostic, high specificity |
| AQP4-IgG (tissue-based assay) |
Positive |
Screening |
| MOG-IgG |
Positive |
Consider MOGAD |
| CSF |
Pleocytosis, OCB negative |
Typical |
| Region |
Typical Findings |
| Optic nerves |
Enhancement, T2 hyperintensity |
| Spinal cord |
Longitudinally extensive (>3 segments), central cord |
| Brain |
Hypothalamic, periventricular, area postrema lesions |
| Feature |
NMOSD |
MS |
| Spinal cord lesions |
Longitudinally extensive |
Short, peripheral |
| Brain lesions |
Hypothalamic, periventricular |
Dawson's fingers |
| Optic nerve |
Longitudinal |
Variable |
- Multiple sclerosis: Different MRI, antibodies
- MOGAD: MOG antibodies positive
- Acute disseminated encephalomyelitis (ADEM): Usually monophasic
- Sarcoidosis: Systemic features
- Behçet's disease: Oral/genital ulcers
- Vasculitis: Systemic involvement
First-line treatment for acute attacks 7:
| Medication |
Dose |
Duration |
| Methylprednisolone |
1 g IV daily |
3-5 days |
| Prednisone taper |
1 mg/kg/day |
Weeks to months |
For incomplete response to steroids 8:
- 5-7 exchanges over 10-14 days
- Initiated within 2 weeks of attack onset
- Particularly effective for AQP4-IgG-positive patients
¶ Maintenance Therapy
Prevention of attacks is critical to prevent disability accumulation:
| Medication |
Dose |
Evidence Level |
| Mycophenolate mofetil |
1-2 g/day |
Strong |
| Azathioprine |
2-2.5 mg/kg/day |
Strong |
| Rituximab |
375 mg/m² weekly × 4 |
Strong |
| Medication |
Indication |
Notes |
| Tocilizumab |
Inadequate response |
IL-6 receptor antagonist |
| Satralizumab |
AQP4+ NMOSD |
Subcutaneous |
| Eculizumab |
Refractory |
Complement inhibitor |
| Inebilizumab |
AQP4+ NMOSD |
CD19 B-cell depletion |
| Symptom |
Treatment |
| Spasticity |
Baclofen, tizanidine, benzodiazepines |
| Pain |
Gabapentin, pregabalin, duloxetine |
| Bladder dysfunction |
Anticholinergics, intermittent catheterization |
| Fatigue |
Modafinil, exercise |
| Depression |
SSRIs, counseling |
| Outcome |
Without Treatment |
With Treatment |
| Median time to disability |
5-7 years |
Extended significantly |
| Vision loss |
Common |
Reduced with treatment |
| Paralysis |
Common |
Less severe |
| Mortality |
20-30% at 5 years |
Improved with modern therapy |
- Positive predictors: Early treatment, sustained maintenance therapy
- Negative predictors: Late treatment, frequent attacks, extensive initial lesions
- AQP4-IgG titer: Higher titers may predict more severe disease
NMOSD and MOGAD share some clinical features but have important differences:
| Feature |
NMOSD (AQP4+) |
MOGAD |
| Target antigen |
AQP4 |
MOG |
| Pathogenesis |
Complement-mediated |
Antibody-mediated (less complement) |
| Brain involvement |
More common |
More common |
| Lesion pattern |
Periventricular, hypothalamic |
Cortical, leptomeningeal |
| Treatment |
Similar but may differ |
Similar |